Clinical trials: Complicated Intra-abdominal Infection
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT01602874
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Pfizer
Intra-Abdominal Infections
Procalcitonin Guided Antibiotic Therapy
The overuse of antibiotics is an enormous problem facing the healthcare system both in the United States and across the world. The investigators plan to test the hypothesis that using procalcitonin levels (blood test) to guide…
- Trial name
- NCT04240288
- Testing
- Procalcitonin-guided antibiotic treatment, Standard of Care Antibiotic Treatment
- Sponsor
- Columbia University
Complicated Intra-abdominal Infections
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
This study aims to evaluate the efficacy of ceftolozane/tazobactam (MK-7625A) plus metronidazole versus meropenem in adults diagnosed with complicated intra-abdominal infection (cIAI).
- Trial name
- 7625ACNPhase3 (NCT03830333)
- Testing
- Ceftolozane/Tazobactam, Metronidazole, Meropenem
- Where
- 25 sites in China
- Volunteers
- 268 people
- Sponsor
- Merck Sharp & Dohme LLC
Appendicitis, Cholecystitis
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
This is a phase 3b/4 randomized, open-label, comparative, multicenter study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI (Complicated Intra-Abdominal…
- Conditions
- Appendicitis, Cholecystitis, Cross Infection, Diverticulitis
- Trial name
- NCT00195351
- Testing
- tigecycline, ceftriaxone sodium + metronidazole
- Where
- 66 sites in United States, Argentina and 4 more
- Volunteers
- 467 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Abdominal Abscess
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI
In light of tigecycline's activity against these resistant bacteria, tigecycline may represent a viable new therapy for complicated intra-abdominal infections.
- Trial name
- NCT00488306
- Testing
- tigecycline
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pharmacokinetics, Antibacterial Agents
Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients
Multidrug resistance towards Gram-negative pathogens makes essential the re-examination of older compounds. Temocillin is a penicillin originally marketed in the 1980s but then largely abandoned.
- Conditions
- Pharmacokinetics, Antibacterial Agents, Infections, Bacterial, Infection
- Trial name
- TEMODELTA (NCT03557840)
- Testing
- temocillin
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Paul M. Tulkens
Complicated Intra-abdominal Infection
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult…
- Trial name
- NCT01265784
- Testing
- TP-434, Ertapenem
- Where
- 38 sites in United States, Bulgaria and 4 more
- Volunteers
- 143 people
- Sponsor
- Tetraphase Pharmaceuticals, Inc
Intra-abdominal Infections
Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125 mg or 250 mg doses of relebactam (MK-7655) to imipenem/cilastatin in adults 18 years or older with Complicated Intra-Abdominal Infection…
- Trial name
- NCT01506271
- Testing
- Relebactam 250 mg, Relebactam 125 mg, Imipenem/cilastatin
- Volunteers
- 351 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Intra-Abdominal Infection
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial…
- Trial name
- NCT00929643
- Testing
- no intervention
- Where
- 13 sites in Greece
- Volunteers
- 203 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
To Evaluate the Effects of Ceftazidime-Avibactam and Best Available Therapy in patients with complicated urinary tract infections and complicated intra-abdominal infections.
- Trial name
- NCT01644643
- Testing
- Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
- Where
- 43 sites in United States, Argentina and 16 more
- Volunteers
- 345 people
- Sponsor
- Pfizer
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (IMI/REL, MK-7655A) in Japanese participants with complicated intra-abdominal infection (cIAI) or complicated urinary tract infection (cUTI).
- Trial name
- NCT03293485
- Testing
- Imipenem+Cilastatin/Relebactam
- Where
- 29 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Appendicitis, Intra-Abdominal Abscess
Laparoscopic Antibiotic Lavage to Prevent Intra-abdominal Abscess Formation in Complicated Appendicitis
Appendicitis is one of the most common causes of acute surgical admission. Presently, two types of appendicitis are distinguished: complicated and uncomplicated (phlegmonous).
- Trial name
- ALPACA (NCT06841003)
- Testing
- Laparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin
- Where
- 11 sites in Netherlands
- Volunteers
- 752 people
- Sponsor
- Spaarne Gasthuis
Infections, Pelvic Infections
An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)
The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute…
- Trial name
- NCT00092170
- Testing
- MK0826, ertapenem sodium, Comparator: Ticarcillin/Clavulanate
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Intra Abdominal Infections
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by…
- Trial name
- NCT03358576
- Testing
- Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 674 people
- Sponsor
- Iterum Therapeutics, International Limited
Bacterial Infections and Mycoses, Appendicitis
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.
- Conditions
- Bacterial Infections and Mycoses, Appendicitis, Cholecystitis, Pancreatitis
- Trial name
- NCT00210938
- Testing
- Doripenem
- Volunteers
- 478 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Appendicitis, Cholecystitis
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment.
- Conditions
- Appendicitis, Cholecystitis, Diverticulitis, Intra-Abdominal Abscess
- Trial name
- NCT00230971
- Testing
- tigecycline, ceftriaxone plus metronidazole
- Where
- 68 sites in Australia, China and 17 more
- Volunteers
- 473 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Intra-Abdominal Infections, Skin Disease, Infectious
Post-Authorization Study Evaluating Safety Of Tigecycline
This is a study to evaluate the safety of tigecycline in patients with complicated intra-abdominal infections (cIAI) and complicated skin and soft tissue infections (cSSTI) under real practice in the usual hospital setting and…
- Conditions
- Intra-Abdominal Infections, Skin Disease, Infectious, Soft Tissues Infections
- Trial name
- HORUS (NCT00827541)
- Testing
- Tigecycline
- Volunteers
- 115 people
- Sponsor
- Pfizer
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT00914888
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infection
A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting
To assess the efficacy and safety of Tygacil in the usual German hospital setting. The main goals are: to assess the efficacy of Tygacil under usual care conditions (cure rate); to assess the main side effects observed in daily…
- Trial name
- NCT00488488
- Testing
- tigecycline
- Volunteers
- 1,028 people
- Sponsor
- Pfizer
Bacterial Infections and Mycoses, Appendicitis
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
The purpose of this study is to compare the clinical response rate of doripenem versus a comparator in the treatment of hospitalized patients with complicated intra-abdominal infections.
- Conditions
- Bacterial Infections and Mycoses, Appendicitis, Cholecystitis, Pancreatitis
- Trial name
- NCT00229060
- Testing
- doripenem
- Volunteers
- 483 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.